Pathology data to advance discovery for HIV cancer patients 

Pathology data for HIV

The AIDS and Cancer Specimen Resource (ACSR), a biorepository of specimens collected from persons living with HIV (PLWH) established in 1994 and funded by the National Institutes of Health, National Cancer Institute, is using software from Proscia to encourage scientific exploration and discovery in cancer in PLWH.  

The ACSR’s mission is to acquire, store, and equitably distribute biospecimens, including tissue-based pathology data, and associated clinical data from PLWH to the scientific community-at-large. Investigators have leveraged its data to drive the development of new diagnostic and treatment approaches for HIV-associated malignancies. As digital pathology shifts the standard from microscope to high-resolution images, the ACSR recognised an opportunity to improve access to its data and drive further breakthroughs by adopting the technology. 

Since selecting Proscia’s Concentriq for Research, the ACSR has reduced the time it takes to provide investigators with pathology data from days to hours. As the enterprise pathology platform facilitates the sharing of images instead of glass slides, the ACSR can transcend geographic barriers and simultaneously share the same datasets so that more research teams can drive scientific advancements. In addition, this approach allows for conservation and increased sustainability of rare and exhaustible tissue specimens to a large number of individual researchers.  

“We are fortunate to have a growing library of rare and valuable biospecimens that have contributed to the fight against cancer in PLWH,” said Dr Paige Bracci, UCSF Professor of Epidemiology and Biostatistics, and Director of the ACSR’s Informatics programme. “Concentriq for Research has enabled us to quickly realise the benefits of digital pathology and get this real-world data in the hands of more researchers faster. Proscia’s platform is not only making a difference for the scientific community but also for the patients impacted by its work.” 

Along with this news, the ACSR has announced the availability of a rare melanoma tissue repository on Concentriq for Research. A corresponding tissue microarray of these tumour tissues will be available in early 2024. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free